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Abstract
Background: There are approximately 35,000 human deaths from rabies in Asia annually. 
Rabies can be prevented through timely post-exposure prophylaxis (PEP) consisting of wound 
washing, rabies vaccine, and in some cases, rabies immunoglobulin (RIG). However, access to 
rabies PEP often remains limited to urban areas and is cost-prohibitive. There is little information 
on procurement, distribution, monitoring, and reporting of rabies PEP.
Methods: We interviewed key informants in the public sector from various levels in Bangladesh, 
Bhutan, Cambodia, and Sri Lanka between March 2017 and May 2018 using a descriptive 
assessment tool to obtain information on procurement, distribution, monitoring, and reporting of 
rabies PEP. These four countries in Asia were chosen to showcase a range of rabies PEP systems. 
National rabies focal points were interviewed in each country and focal points helped identify 
additional key informants at lower levels.
Results: A total of 22 key informants were interviewed at various levels (central level to health 
facility level) including national rabies focal points in each country. Each country has a unique 
system for managing rabies PEP procurement, distribution, monitoring, and reporting. There are 
varying levels of PEP access for those with potential rabies exposures. Rabies PEP is available in 
select health facilities throughout the country in Bangladesh, Bhutan, and Sri Lanka. In Cambodia, 
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rabies PEP is limited to two urban centers. The availability of RIG in all four countries is limited. 
In these four countries, most aspects of the rabies PEP distribution system operate independently 
of systems for other vaccines. However, in Bhutan, rabies PEP and Expanded Programme on 
Immunization (EPI) vaccines share cold chain space in some locations at the lowest level. All 
countries have a monitoring system in place, but there is limited reporting of data, particularly to 
the central level.
Conclusion: Systems to procure, deliver, monitor, and report on rabies PEP are variable across 
countries. Sharing information on practices more widely among countries can help programs to 
increase access to this life-saving treatment.
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1. Introduction
Rabies is caused by a lyssavirus and is nearly 100% fatal once clinical symptoms occur. 
Worldwide, rabies causes an estimated 59,000 human deaths annually with approximately 
60% of cases occurring in Asia [1]. The total number of deaths is likely an underestimate 
due to poor surveillance and reporting, and a lack of laboratory testing capacity [1–3].
Rabies in humans can be prevented through timely and appropriate post-exposure 
prophylaxis (PEP). Rabies PEP consists of wound washing, immediate rabies vaccination 
following the potential exposure, and in some cases, rabies immunoglobulin (RIG). 
Currently only cell-culture or embryonated egg-based rabies vaccines (CCEEVs) are 
recommended by the World Health Organization (WHO); the original nerve-tissue based 
vaccine (NTBV) has not been recommended since the 1980s [3,4]. Very few countries in the 
world continue to use NTBV.
WHO provides guidance for rabies PEP according to three categories of bites (Fig. 1) [3]. 
Rabies vaccine is recommended for all Category II and III bites, whereas RIG is only 
recommended for Category III bites; however, less than 2% of patients worldwide who need 
RIG actually receive it [3,5–8]. Rabies vaccine can be administered by the intramuscular 
(IM) route, using a full vaccine vial per patient, or by the intradermal (ID) route, using a 
fractional dose [8]. Vaccination schedules and dosage vary by route of administration [8]. 
Fractional ID administration is cost-, dose-, and time-sparing as compared to IM 
administration [8]. Without PEP, an estimated 3 million people worldwide would die from 
rabies annually [1].
In 2015, WHO, the World Organization for Animal Health (OIE), the Food and Agriculture 
Organization of the United Nations (FAO) and the Global Alliance for Rabies Control 
(GARC) established a global goal of zero dog-mediated human rabies deaths by 2030[9]. 
The Association of Southeast Asian Nations (ASEAN) and the Plus Three Countries (China, 
Japan, and Korea) developed a regional strategy to eliminate rabies by 2020 and the WHO 
Southeast Asia Region developed a regional strategy to eliminate human rabies transmitted 
by dogs by 2020 [10,11]. Sri Lanka developed a national strategy to eliminate human deaths 
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by rabies by 2020 [12]. All strategies include collaboration among partners and illustrate the 
“One Health” approach in which the animal and human health sectors work together to 
achieve the goal. While rabies PEP is effective in preventing human rabies deaths, animal 
rabies control is the solution for rabies elimination and animal rabies control is a main pillar 
of each of these strategies. However, there have been varying degrees of progress toward 
reaching these goals. For human rabies prevention, access to rabies PEP continues to be 
cost-prohibitive and availability is largely restricted to urban areas.
Knowledge on rabies PEP procurement and distribution is limited, and there is little 
information on monitoring and reporting of its use. This project was part of a larger global 
project conducted in 23 countries to better understand rabies PEP systems; results can be 
found in Overview of rabies post-exposure prophylaxis access, procurement and distribution 
in selected countries in Asia and Africa, 2017–2018 (Sreenivasan, unpublished results). 
Bangladesh, Bhutan, Cambodia, and Sri Lanka were chosen for in-depth assessments to 
highlight unique aspects of delivery and distribution systems in Asia. We aimed to include 
countries with varying burdens of human rabies and varying levels of effort to control and 
eliminate rabies, as well as countries in both the Southeast Asia and Western Pacific WHO 
regions and countries in various categories of eligibility for support from Gavi, the Vaccine 
Alliance (eligible, non-eligible and transitioning) [11–21]. This paper outlines procurement, 
distribution, monitoring, and reporting systems of rabies PEP in four countries with diverse 
delivery systems in the Asia region (Bangladesh, Bhutan, Cambodia, and Sri Lanka), with an 
emphasis on the vaccine component of PEP, and aims to summarize practices from each 
country in order to identify areas for improving access to PEP.
2. Methods
We interviewed key informants to obtain information on procurement, distribution, 
monitoring, and reporting of rabies PEP, using a descriptive assessment tool. The tool 
consisted of ten categories of questions on program delivery, vaccine procurement, demand, 
distribution, cold-chain and vaccine storage, forecasting, monitoring, utilization, and 
reporting. Key informants were identified at each level of the healthcare system based on the 
structure of the country’s healthcare and rabies PEP system (e.g. central, province, district, 
health facility) and included national rabies focal points and health facility heads. When 
possible, we also interviewed other key informants such as Expanded Programme on 
Immunization (EPI) focal points to gain a more comprehensive understanding of 
immunization programs in the countries. Additionally, we reviewed vaccination registers to 
understand the monitoring system of rabies PEP and type of information recorded on bite 
patients and evaluated cold chain capacity at health facilities visited. We collected data 
between March 2017 and May 2018. To provide background information on the rabies 
situation in each country, we also reviewed WHO documents and published studies on rabies 
relevant to the selected countries.
3. Results
A total of 22 individuals were interviewed in the four countries. In each country, the national 
rabies focal point was interviewed, some with over 20 years of experience in the role. Other 
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individuals interviewed included national-level staff working on rabies (5), WHO country 
office rabies focal points (2), national-level EPI staff (2), WHO country office EPI staff (2), 
and health facility heads and health workers (7). In some countries, health facilities were not 
visited specifically for this assessment and thus are not included in the total number 
interviewed, but were visited by national rabies focal points as part of their routine work. 
Table 1 provides an overview of the main aspects of each rabies PEP system from the 
country assessments, with additional description provided for each country below.
3.1. Bangladesh
In Bangladesh, there are an estimated 2000 deaths due to rabies with over 166,000 animal 
bite victims, the majority of which are dog-bite victims, annually [15]. Rabies became a 
national priority in Bangladesh in 2011 with the phase-out of NTBV and introduction of 
CCEEV administered using the ID route, establishment of an elimination strategy through a 
“One Health” approach, strong political commitment and budget allocation, and regular 
large-scale animal vaccination program [15,17,18,22].
Rabies PEP is offered at 66 public District Rabies Prevention and Control Centers 
(DRPCCs) around the country with at least one center in each of the 64 districts and at a 
National Rabies Prevention and Control Center (NRPCC). The NRPCC provides treatment 
to approximately 500 patients daily [23,24]. At public treatment centers, patients do not pay 
for vaccine or RIG, but pay a small amount for a disposable syringe (US$ 0.13). If rabies 
PEP is out of stock at a public facility, patients must purchase it at a pharmacy (US$ 8.25 per 
vaccine vial and US$ 12.50 per vial of RIG). The cost of the vaccine can be shared among 
several patients, as the ID administration route allows one vial to provide several doses [25].
The Ministry of Health (MoH) uses an open bidding system to select the vaccine provided in 
public facilities. The timeframe from bidding to delivery is six months to one year. Central 
level procurement is based on the previous years’ consumption through the Communicable 
Disease Control (CDC) operational plan of the Directorate General of Health Services 
(DGHS). Since 2014, CDC/DGHS has procured 20–30% more vaccine each year than the 
previous year, but PEP demand continues to exceed the supply due to increasing public 
awareness. CDC/DGHS strives to fulfill 100% of the demand year-round at the NRPCC, and 
50–80% of the demand at DRPCCs. Rabies focal points from the DRPCCs are responsible 
for collecting vaccine monthly from the central medical store. Collection requires prior 
approval for the amount requested from CDC/DGHS and a report on the previous month’s 
utilization. Focal points are responsible for transporting vaccine back to treatment centers 
using cold boxes and ensuring storage of vaccines in a refrigerator at the DRPCCs. This 
system is separate from the EPI program as the EPI program transports routine vaccines 
from the capital to regional centers and then to the local level using their own mechanisms.
CDC/DGHS provides a standardized register to track patients, record demographics, and 
monitor vaccine usage, as well as a standardized rabies vaccination card for patients. 
Patients are also given a reminder card for future appointments. The NRPCC and DRPCCs 
are required to report the total number of doses and the dates of administration to CDC/
DGHS through the National Health Management Information System (MIS-DHIS2) on a 
monthly basis and reports are aggregated at the central level for planning purposes. The 
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NRPCC and DRPCCs also submit a hard-copy report detailing patient demographic and 
bite-related information to CDC/DGHS for future planning purposes. There is no formal 
system for monitoring and reporting adverse events following rabies PEP; instead, 
information on adverse events is collected and reported ad hoc to CDC/DGHS. There is 
currently no follow-up of defaulters and individual vaccine completion rates are not 
checked. However, CDC/DGHS is establishing a regular mobile phone-based monitoring 
system to identify adverse events and to detect reasons for incompletion of the vaccination 
schedule.
3.2. Bhutan
In Bhutan there were over 7900 reported dog bites and one rabies death in the country in 
2016 [26,27]. The Bhutan Ministry of Health updated their National Rabies Management 
Guidelines in 2014 [28]. Bhutan has emphasized a “One Health” approach bringing together 
both dog and human rabies prevention and control strategies [14,28,29].
Bhutan’s healthcare system consists of one national, two regional-level, and 30 district 
hospitals, and 210 basic health units (BHU-I and II), as well as indigenous and outreach 
clinics throughout the country [27]. Rabies vaccine is provided free of charge at BHU-II or 
higher health facilities and is administered using the ID route [29]. RIG is provided free of 
charge on a more limited basis at BHU-I or higher facilities due to high costs. According to 
Bhutan’s rabies management guidelines, all Category III patients should receive RIG but 
because of the limited supply due to the high cost, the majority of these patients are not 
given RIG [8,28,29]. In line with Bhutan’s integrated service delivery policy, rabies vaccine 
is given by the same staff as EPI vaccines; staff are trained by both programs. Rabies PEP is 
unavailable in the private sector.
All drugs including rabies vaccines are procured through the Medical Procurement and 
Supplies Division (MSPD) of the MoH while EPI vaccines are procured by Vaccine 
Preventable Disease Control Program (VPDP) through UNICEF. Head pharmacy technicians 
submit annual rabies vaccine requests based on the previous year’s consumption with a one-
month buffer. Requests are submitted to the Health Care and Diagnostic Division (HCDD) 
using a standardized form for all drugs. The HCDD verifies the quantities of rabies vaccine 
requested and submits the request to the MSPD. The MSPD receives rabies vaccines and 
they are then distributed in a cold chain van to the hospital level. BHUs then request and 
collect rabies vaccine from their respective district hospitals as needed. Within some health 
facilities, rabies vaccines and EPI vaccines are stored together. Rabies vaccine distribution 
was previously integrated with EPI vaccines as an interim measure until resources were 
made available to separate the two systems.
All health facilities that provide rabies PEP are required to maintain a vaccine inventory 
stock ledger and rabies vaccine register with demographics, information on exposure, and 
vaccination dates. However, there is no mandatory reporting requirement or system to report 
rabies PEP data, nor are the data monitored at the central level [29]. Vaccination cards 
included with the vaccine vials are given to patients when available. There is no system for 
following-up with defaulting patients or documenting individual series completion rates 
unless the patient is bitten by a confirmed rabid dog. These patients are followed-up by a 
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phone call if they do not return for their additional vaccine doses. Suspected adverse events 
following PEP are reported using the Adverse Drug Reactions (ADR) form to the 
Pharmacovigilance unit within the Drug Regulatory Agency; this system is also used for 
other drugs and vaccines.
3.3. Cambodia
There are an estimated 800 human rabies deaths annually in Cambodia with over 700,000 
people bitten by dogs each year; dog vaccination campaigns are not conducted regularly 
[14,30]. There is no national rabies control program but a national strategy is under 
development.
Three non-private entities provide rabies PEP in Cambodia: Angkor Hospital for Children 
(AHC) in Siem Reap and the Institut Pasteur du Cambodge (IPC) rabies vaccination center 
and National Institutes of Public Health (NIPH) clinic in Phnom Penh. Children ≤16 years 
can receive PEP free of cost at the AHC. Patients of all ages can access rabies vaccine (US
$ 12 for the full course) and RIG (US$ 37) at subsidized costs at IPC in Phnom Penh. At 
both AHC and IPC, RIG is only available in limited quantities and patients are prioritized 
based on status of dog, wound location, and age. IPC receives approximately 22,000 new 
patients for PEP annually and AHC receives around 3000 patients. Rabies vaccine is 
available at full cost (US$ 8–15 per dose depending on brand) at the NIPH clinic; RIG is not 
available. The NIPH clinic receives around 500 new patients each year. Rabies vaccine is 
administered using the ID administration route at AHC and IPC and intramuscular (IM) 
administration route at NIPH clinic. Additionally, rabies vaccine is widely available at a 
number of private clinics throughout the country, with some also offering RIG. Public health 
facilities outside of Phnom Penh will often refer adult patients to the private sector for 
treatment. However, there is limited knowledge of the availability, quality, and cost of PEP at 
these private clinics.
All three clinics have a procurement focal point. Forecasting is done based on the previous 
month’s (or several months’) consumption. Vaccines and RIG are purchased directly from a 
supplier in Phnom Penh and delivered directly to the hospital or clinic, as needed. Vaccines 
are stored in refrigerators either in the immunization room or in a store room and transferred 
to a vaccine carrier for daily use.
The NIPH clinic and IPC use electronic databases for stock monitoring and reporting with 
standardized information collected on patients including demographics, vaccine brand, 
administration route, WHO bite category, status of dog, and PEP vaccination dates. AHC 
records similar information in a hard-copy stock ledger and patient chart. Each facility 
provides their own vaccination card to their patients. There are no mandatory reporting 
requirements of rabies PEP or patients receiving rabies PEP to the MoH. The NIPH clinic 
reports the numbers of people receiving rabies vaccine at the clinic to NIPH monthly. NIPH 
then reports the numbers to MoH. IPC reports annually to the MoH or when requested. AHC 
does not report to the MOH on rabies vaccination. There is limited defaulter tracking in all 
facilities with follow-up done ad hoc and only for those with probable rabies exposures (e.g. 
confirmed rabid biting animal), and no system for monitoring of adverse events.
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3.4. Sri Lanka
Sri Lanka has had a national rabies control program since 1975 and human rabies has been a 
notifiable disease since 1971 [12,16,31]. Each year approximately 150,000 people are bit by 
an animal, the majority of which are dogs, but the government’s commitment to rabies 
control has resulted in substantial progress in reducing rabies deaths to 20 deaths reported in 
2016, as compared to 50–60 deaths reported annually for much of the 2000s [12,31–33]. 
This progress is attributed to measures such as making rabies a national health priority, 
providing PEP for free, and animal-sector efforts including dog vaccination [12,13,16].
Rabies PEP is provided for free at the 204 rabies units located in hospitals throughout the 
country. Higher volume hospitals carry both vaccine and RIG; lower levels only carry rabies 
vaccine. Rabies units have at least one bed and one computer for electronic reporting, and 
are staffed with doctors and nurses trained on PEP protocols. PEP is also available in the 
private sector on a limited basis and at high cost.
Rabies PEP is procured at the central level by the State Pharmaceutical Corporation of Sri 
Lanka (SPC) and arrives in three stocks annually. SPC is required to procure WHO pre-
qualified vaccines. Each rabies unit prepares an annual request based on the previous year’s 
vaccine use. All rabies units use the same standardized form as for other drug and vaccine 
requests. Rabies PEP are transported from the central to the regional to the district level 
either by refrigerator truck or by cold box throughout the year according to a delivery plan 
decided by the government. Within rabies units, PEP is stored in its own refrigerator. Within 
emergency rooms, it is stored in ward refrigerators, along with other non-rabies biologicals. 
Rabies PEP arrives in the country throughout the year, but is often issued to health facilities 
in smaller stocks because of space shortages. Additional stocks are kept at the district or 
central level, and sent to facilities as needed.
Each unit maintains an electronic or paper-based patient register with information on patient 
demographics, animal involved and status, and dates of vaccination. Some rabies units have 
transitioned to a real-time online data reporting system with other units expected to enhance 
reporting systems soon. All patients receive a printed PEP card with the dates of subsequent 
visits. Each unit also has a register for stock monitoring showing daily, weekly, monthly, and 
yearly balances. Rabies units are required to report on rabies PEP stock and the numbers of 
individuals receiving PEP monthly to the anti-rabies campaign at the MoH. Defaulter 
tracking is done for all patients that are considered high risk based on the location or severity 
of the wound and biting animal status. If a patient is considered high risk, follow-up is done 
by phone or in-person by a rabies public health inspector (one per district). Adverse events 
following rabies vaccination is reported through the adverse event reporting system, as with 
other vaccines.
4. Discussion
The countries described have differently structured systems for rabies vaccine procurement, 
distribution, monitoring, and reporting. Bangladesh, Bhutan, Cambodia, and Sri Lanka also 
had varying levels of access to rabies PEP for persons with potential exposure. Because of 
the low numbers of patients requiring rabies PEP, as compared to other types of treatments, 
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PEP can be made accessible without being available at every level of the healthcare system 
or every health facility [34]. In Bangladesh, Bhutan, and Sri Lanka, rabies vaccine is 
available at selected health facilities in every district either integrated into existing health 
services or in designated rabies units. In addition to providing physical access, Bangladesh, 
Bhutan, and Sri Lanka provide rabies vaccine free or at a nominal cost within the public 
sector. Accessibility and low cost in these countries may also be partially attributed to the 
presence of a national rabies program.
Throughout the four countries, availability of RIG is limited, and is cost-prohibitive to 
governments and patients. When available, its use is often prioritized for young children, 
patients with severe wounds or wounds at highly innervated body parts, or in exposures to 
probable or confirmed rabid animals. This prioritization is in line with the 2018 WHO 
position on rabies immunization emphasizing dose- and cost-sparing approaches [8].
Rabies vaccine distribution systems in these four countries primarily operate independently 
of systems for other vaccines. Bangladesh’s distribution system requires district level 
facilities to collect rabies vaccines from a central location. In Sri Lanka, rabies vaccine is 
delivered from the central level to the lower level facilities. In Cambodia, all three non-
private rabies PEP providers work directly with the supplier to have rabies vaccines 
delivered. Bhutan provides an example of rabies vaccines being successfully incorporated 
into existing EPI distribution structures while awaiting development of a rabies vaccine-
specific distribution network. Even with a separate distribution network, rabies PEP is stored 
in refrigerators with EPI vaccines at some Bhutan health facilities. Additionally, some 
Bhutan EPI staff administer rabies vaccine. EPI staff receive extensive training on 
immunization practices and EPI’s cold storage is closely monitored which provides 
assurance that the cold chain for rabies PEP remains intact.
There is limited collection and reporting of data on demographics of patients, bite 
categories, barriers to PEP access and factors affecting adherence to vaccination schedules 
and completion in most countries. In some cases, this information is collected at the local 
level. For example, in Cambodia, NIPH clinic collects detailed information on each patient 
through a comprehensive electronic database [34]. However, this information is not always 
reported to the central level. While Bhutan provides monitoring tools to health facilities, 
information is not reported to the central level, and some entities in Cambodia only report on 
an ad hoc basis, as reporting is not mandatory. This information is needed to understand 
vaccine uptake and demand, where to allocate the vaccine, and how to improve access to 
rabies PEP.
Rabies PEP systems in these four countries have several good practices that may be valuable 
to share. Exploring these systems provides an opportunity to learn and tailor country 
programs with the aim of increasing access to life-saving rabies prophylaxis. Additionally, 
rabies PEP management and delivery systems can be adapted from existing systems, such as 
those of the EPI program. EPI programs often include extensive trainings on administration 
and cold chain, and standardized guidelines on vaccine introduction, defaulter tracking, and 
adverse event reporting. These aspects could be leveraged to strengthen rabies PEP 
distribution systems. There are currently no global standardized protocols for country rabies 
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PEP systems. While unique aspects of countries mean that it is not feasible to implement the 
same system everywhere, a standardized set of recommendations would help countries to 
develop effective systems tailored to the country context. Although this assessment focused 
solely on human rabies PEP, elimination of human rabies deaths cannot be done with rabies 
PEP alone. Achievement of elimination targets will require the collaborative efforts of the 
human, animal and other sectors [2,4,9,10,12,35–39].
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Fig. 1. 
Categories of contact with suspect rabid animal and post-exposure prophylaxis (PEP) [3,8].
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